Agenus Reports 100% Major Pathologic Response in dMMR Combination Cohort
In the 14-patient dMMR/MSI-H BOT+BAL cohort, all patients achieved a major pathologic response and 13 (93%) achieved a complete response. At the February 9, 2026 cutoff, no BOT+BAL patients had recurrence; 12-month event-free survival was 100% in both combination cohorts.
In the 14-patient dMMR/MSI-H BOT+BAL cohort, all patients achieved a major pathologic response and 13 (93%) achieved a complete response. At the February 9, 2026 cutoff, no BOT+BAL patients had recurrence; 12-month event-free survival was 100% in both combination cohorts.Material DetailsContext by…